Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rivaroxaban vs Aspirin in Rheumatic Heart Disease (INVICTUS-ASA)
NCT02832531Phase 3Withdrawn
- Sponsor
- Population Health Research Institute
- Start
- Jan 2022
- Primary completion
- Apr 2022
- Modality
- Small Molecules
01
Overview
A Phase 3 trial of rivaroxaban in rheumatic heart disease (RHD), sponsored by Population Health Research Institute. Planned start Jan 2022; status: withdrawn.
02
Drugs
rivaroxaban
03
Conditions
rheumatic heart disease (RHD)
Beyond the preview
Go deeper on NCT02832531.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02832531.